Who is sponsoring NCT04693546?

NCT04693546 is sponsored by Metabiomics Corp.

What drugs are being tested in NCT04693546?

Interventions in NCT04693546: LifeKit Prevent Colorectal Neoplasia Test, FIT Test.

What condition does NCT04693546 study?

NCT04693546 studies Colorectal Cancer, Colorectal Adenoma.

Is NCT04693546 still recruiting?

NCT04693546 is currently suspended. Last updated 26 September 2025.

Last reviewed 2025-09-26 · How we verify

NCT04693546: PREVENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for CRC Screening

Suspended Last updated 26 September 2025

What this trial tests

trial testing LifeKit Prevent Colorectal Neoplasia Test in Colorectal Cancer in 12,000 participants. Suspended.

Timeline

1 March 2026

Primary endpoint
1 December 2027

1 March 2028

Quick facts

Lead sponsor	Metabiomics Corp
Status	Suspended
Study type	OBSERVATIONAL
Enrollment	12,000
Start date	1 March 2026
Primary completion	1 December 2027
Estimated completion	1 March 2028
Sites	1 location across United States

Drugs / interventions tested

LifeKit Prevent Colorectal Neoplasia Test
FIT Test

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Colorectal Adenoma — all drugs for Colorectal Adenoma →

Sponsor

Metabiomics Corp

Who can join

40 and older, any sex, with Colorectal Cancer or Colorectal Adenoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the sensitivity and specificity for LifeKit Prevent Colorectal Neoplasia Test for colorectal cancer (CRC) and for adenoma, including advanced adenoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04693546 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Metabiomics Corp
Last refreshed: 26 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04693546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing